Skip to main content

Table 3 Univariate analysis for PFS

From: EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition

 

Correlative cohort (n = 66)

Anti-EGFR treated (n = 39)

 

Median

p

Median

p

Smoking history

 

0.246

 

0.238

  Never smokers

5.0

 

3.2

 

  Former smokers

5.0

 

5.6

 

  Current smokers

7.0

 

10.0

 

Stage

 

0.130

 

0.423

  IIIB

7.6

 

11.4

 

  IV

5.0

 

4.8

 

Age

 

0.233

 

0.894

<70 years

5.5

 

7.2

 

70years

6.5

 

5.0

 

EGFR mutation*

 

0.373

 

0.052

  Exon 19 mutation

4.4

 

12.7

 

  Exon 20 mutation

8.0

 

NA

 

  Exon 21 mutation

3.2

 

1.4

 
  1. Abbreviations: PFS progression-free survival, NA not applicable. *Analysis is restricted to EGFR mutant patients only.
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us